Comparing the current results to its competitors, Alnylam Pharmaceuticals Inc reported Revenue increase in the 2 quarter 2026 by 66.86 % year on year. The sales growth was above Alnylam Pharmaceuticals Inc 's competitors' average revenue growth of 8.9 %, achieved in the same quarter.
Alnylam Pharmaceuticals Inc achieved net profit of $164.49 millions compared to a net loss of $-66.28 millions recorded in the same quarter a year ago.
Due to outstanding performance in Overall company, revenue grew by 66.86 % Alnylam Pharmaceuticals Inc improved its market share, to approximately 2.95 %.
June 24, 2024
Alnylam Pharmaceuticals Announces Groundbreaking Phase 3 HELIOS-B Study Results for Vutrisiran CAMBRIDGE, Mass. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) , the pioneering company in RNA interference (RNAi) therapeutics, has announced outstanding topline results from its HELIOS-B Phase 3 study concerning vutrisiran, an investigational RNAi therapeutic. Vutrisiran is being developed to treat transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). The study’s outcomes demonstrated statistically significant benefits in both primary and secondary endpoints across both overall and monotherapy populations, marking a pivotal advancement in ATTR-CM treatment. The Essence of the HELIOS-B Phase 3 Stud...
Publicly Traded Peers of Alnylam Pharmaceuticals Inc
Prelude Therapeutics Inc Share Performance
-14.93%
30 Days
Prelude Therapeutics Inc
Profile
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Ars Pharmaceuticals Inc is a pharmaceutical company that specializes in developing and commercializing innovative drugs for ophthalmic diseases. They focus on creating novel therapies to address unmet medical needs in the field of eye health. Their business model revolves around conducting research, clinical trials, and partnerships to bring their drugs to market and improve patient outcomes.
Enanta Pharmaceuticals Inc's business model focuses on the research, development, and commercialization of innovative small molecule drugs targeting viral infections and liver diseases.
Sources:
Alnylam Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Alnylam Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
